Refine by
T Cell Receptor Therapies Articles & Analysis
78 news found
Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business combination with Tevogen ...
Cartherics’ CEO, Professor Alan Trounson, was recently interviewed by CGTLive, to discuss the company’s development of NK cell, T-cell and macrophage cell therapies for various solid tumours. Cartherics is using its induced pluripotent stem (iPS) cell platform to develop NK cell, T-cell, and macrophage cell therapies with potential indications for solid tumour types including ...
Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T cells bearing the TAG-72 CAR. ...
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. Partnered with the Dunbar CAR T-Cell Program at the University of Louisville as the GMP manufacturing center for INB-400. Strengthened the balance sheet through an equity offering raising net ...
Creative BioMart, a biotechnology company that offers a wide range of solutions dedicated to helping researchers and pharmaceutical companies discover and develop novel drugs in the treatment of cancer, autoimmune diseases, etc., now offers MHC solutions for cell therapy and vaccine development. According to the official speaker from Creative BioMart, based on MHC-like complexes that can ...
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous ...
Galapagos NV (Euronext & NASDAQ: GLPG) today held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company. The company also presented its financial results for the third quarter of 2022. Paul Stoffels3, CEO and Chairman of the Board of Directors of Galapagos, commented: “Today we ...
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML). Clinical activity observed includes continuing robust durability of relapse-free survival; all three patients in Cohort 1 remain alive and progression-free; ongoing durations of response exceed 12 months and extend beyond 25 months. To date, INB-100 ...
We hope to establish our pipeline products as the preferred combination agents with T cell checkpoint inhibitors and other standard of care therapies.” The Phase 1 expansion phase includes IO-108 monotherapy cohorts and IO-108 combination cohorts with anti-PD-1 antibodies (pembrolizumab or cemiplimab, depending on tumor types). ...
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for ...
Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studies Potential to expand the agreement to support commercial-scale manufacturing NEW YORK and LOUISVILLE, Ky, Sept. 15, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell ...
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced that the underwriter of its previously announced underwritten public offering of common stock which closed on August 16, 2022 has partially exercised ...
” The commencement of the Phase III trial transitions the Company into pre-commercialization activities, which include: Working with the FDA in preparation for a BLA submission and commercial launch Implementing a global strategy for launching GP2 in international markets outside the US and Europe Initiating large scale manufacturing, packaging, and marketing The Company ...
All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year. Patients remain in morphological complete remission (CR) with two patients over two years and a third over one year post-transplant, respectively. Safety profile continues to be manageable with no ...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cells Patent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant Immunotherapy platform NEW YORK, July 21, 2022 (GLOBE ...
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive team to lead the Company’s business development efforts. Kenneth R. LaMontagne, Ph.D., joins the company as Senior ...
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management. Ms Harrison joins Chimeric with more than 10 years experience in clinical operations, compliance, and data ...
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) ...
(Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced preliminary, blinded data from an ongoing Phase 2 study of posoleucel, an investigational, allogeneic, off-the-shelf, multi-virus-specific T cell (VST) therapy, for the treatment of BK viremia (BKV) in adult kidney ...
ByKalaris
The investigators did not observe any cases of cytokine release syndrome (CRS), neurotoxicity or graft versus host disease often associated with T-cell therapies. In general, side effects observed in the trial were transient and did not lead to treatment delays or discontinuation. ...